Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$471.11 USD
+3.11 (0.66%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $471.15 +0.04 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 61 - 80 ( 336 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Thoughtful Design of Inaxaplin (VX-147) Aims for Accelerated Approval; Reit. Buy and Raising PT to $300
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
EHA Data from CTX001 Program Looks Promising as the Potential CRISPR-Based Therapy in TDT and SCD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
ADA Data Stresses on Safety and Efficacy of VX-880 - Our Insights
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Our Insights on Safety Concerning Regulatory Submission of CTX001
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
VX-548 Trumps Opioids in Two Phase 2 POC Studies in Acute Pain-Our Thoughts on Phase 3 Design
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
VX-147 Phase 3 Trial Design Might Get an A+ from Nephrologists
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
KOLs Believe Accelerated Approval of VX-147 with Proteinuria Possible
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Expectations for the VX-548 Phase 2 Trials Concerning SPID-Our Insights
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department